Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Infectious & Toxicology
Filter     Order     Display # 
Date Item Title
26 Sep 2007 VaxInnate Initiates Phase I Clinical Study of M2e Universal Influenza Vaccine
25 Sep 2007 Results presesented at ECCO 2007 further confirm the clinical efficacy of BioAlliance Pharma's antifungal particularly in populations with high risk of candidiasis
25 Sep 2007 European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
25 Sep 2007 Pacgen Announces Advances in PAC-113 Program
25 Sep 2007 Pfizer's Celsentri(R) Approved in the European Union, Providing a Novel Treatment Option for Treatment-Experienced HIV Patients
24 Sep 2007 Merck Serono's Cyanokit(R) Recommended For European Approval
22 Sep 2007 Maxygen Announces Hold on MAXY-alpha Development Program
22 Sep 2007 Vaccination and Enrollment Are Discontinued in Phase II Trials of Merck's Investigational HIV Vaccine Candidate
21 Sep 2007 Lytix to Take Lead Antimicrobial Compound into Clinic
21 Sep 2007 FDA Accepts New Drug Application For Priority Review Of Investigational HIV Treatment TMC125
21 Sep 2007 European licence for Roche HIV drug Viracept recommended for re-instatement
20 Sep 2007 Arpida Presents Preclinical and Clinical Data on AR-709 at ICAAC
20 Sep 2007 Replidyne's Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
20 Sep 2007 MethylGene Presents Preclinical Data for its Clinical Candidate MGCD290, an Antifungal Histone Deacetylase Inhibitor
20 Sep 2007 FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
20 Sep 2007 Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
20 Sep 2007 Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
20 Sep 2007 Biocryst Reports Preliminary Results from A Phase II Clinical Trial of Peramivir in Subjects with Acute Influenza
20 Sep 2007 New Topical Therapy Safely Treats Serious Skin Infections
19 Sep 2007 Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
19 Sep 2007 Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study
19 Sep 2007 RDEA806, A Potent, New HIV NNRTI With a High Genetic Barrier to Resistance and a Broad Spectrum of Activity, Introduced at 47th ICAAC
19 Sep 2007 Long-Term Data Reinforce Safety and Efficacy Profile of Pfizer's New HIV Drug Selzentry(TM) (Maraviroc)
19 Sep 2007 Ambrilia Presents Latest Data on its Novel HIV Integrase Inhibitors at the 47th ICAAC
19 Sep 2007 New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
19 Sep 2007 Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic
19 Sep 2007 VIRxSYS Presents Update on HIV Gene Therapy Clinical Trial at ICAAC
18 Sep 2007 Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at Low Dosage
18 Sep 2007 Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
18 Sep 2007 Scientific results presented at ICAAC demonstrate the well-differentiated profile and broad spectrum of BioAlliance Pharma's antifungal
18 Sep 2007 Idera Pharmaceuticals Initiates Phase 1 Trial of IMO-2125 in Hepatitis C
18 Sep 2007 FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
15 Sep 2007 Basilea Announces Positive Top-line Data from Phase III Study of Ceftobiprole in Community-acquired Pneumonia Requiring Hospitalization
14 Sep 2007 Lipsovir(R) - All Patients in the Phase III Program Now Enrolled
13 Sep 2007 Hollis-Eden Pharmaceuticals Reports on Anti-Inflammatory Activity with HE3286 in Models of Diseases of Inflammation
12 Sep 2007 Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
12 Sep 2007 Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
12 Sep 2007 Inhibitex Licenses HIV Integrase Inhibitor Program
11 Sep 2007 R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
11 Sep 2007 GenVec to Develop New Malaria Vaccine for the U.S Military
08 Sep 2007 MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
07 Sep 2007 Cubist Pharmaceuticals' CUBICIN Approved for Additional Indications in the EU
07 Sep 2007 Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
07 Sep 2007 Theravance Retains Full Ownership of Gastrointestinal Motility Dysfunction Program and TD-1792 Antibiotic
06 Sep 2007 Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
06 Sep 2007 Cubicin(R) receives European approval to expand use to treating two additional types of life-threatening hospital infections
05 Sep 2007 Over 80% of patients on ATC achieve undetectable HIV after 24 weeks
05 Sep 2007 Theratechnologies completes patient recruitment for tesamorelin in confirmatory Phase 3 trial
04 Sep 2007 InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
04 Sep 2007 Tibotec Pharmaceuticals Ltd returns MIV-210 licensing rights to Medivir
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 451 - 500 of 1267

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics